The Effect of Serum 25-Hydroxyvitamin D on Serum Ferritin Concentrations: A Longitudinal Study of Participants of a Preventive Health Program

Lalani L. Munasinghe 1, John P. Ekwaru 1, Silmara S. B. S. Mastroeni 2, Marco F. Mastroeni 3* and Paul J. Veugelers 1,*

1 School of Public Health, University of Alberta, Edmonton, AB T6G 2T4, Canada; munasing@ualberta.ca (L.L.M.); ekwaru@ualberta.ca (J.P.E.)
2 Department of Physical Education, University of Joinville Region, Joinville 89219-710, SC, Brazil; silmara.mastroeni@univille.br
3 Post-graduation Program in Health and Environment, University of Joinville Region, Joinville 89219-710, SC, Brazil; marco.mastroeni@univille.br
* Correspondence: paul.veugelers@ualberta.ca; Tel.: +1-780-492-9095

Received: 8 February 2019; Accepted: 18 March 2019; Published: 23 March 2019

Abstract: Various studies have suggested a role of vitamin D in inflammation. However, its effect on ferritin, a biomarker of inflammation, has received relatively little attention. Therefore, we aimed to assess the association of serum 25-hydroxyvitamin D (25(OH)D) with serum ferritin (SF) concentrations, and to examine whether temporal increases in serum 25(OH)D concentrations are paralleled by a reduction in SF concentrations. Data from a community sample of Canadian adults who participated in a preventive health program (n = 6812) were analyzed. During the follow-up, serum 25(OH)D concentrations increased from 80.7 to 115.0 nmol/L whereas SF concentrations decreased from 122.0 to 92.0 µg/L (median follow-up time was 11.67 months). Cross-sectional analyses revealed that compared to participants with 25(OH)D concentrations of <50 nmol/L, those with 25(OH)D concentrations of 75 to <100, 100 to <125, and ≥125 nmol/L had SF concentrations that were 13.00, 23.15, and 27.59 µg/L lower respectively (p < 0.001). Compared to those without temporal improvements in 25(OH)D concentrations between baseline and follow-up, participants who improved their 25(OH)D concentrations with ≥50 nmol/L decreased their SF concentrations with 5.71 µg/L. For participants for whom the increase in 25(OH)D concentrations was less than 50 nmol/L, decreases in SF concentrations were less pronounced and not statistically significant. These observations suggest that despite strong associations between 25(OH)D and SF concentrations, interventions aiming to lower SF concentrations through sun-exposure and vitamin D supplementation should target substantial increases in 25(OH)D concentrations.

Keywords: serum ferritin; vitamin D; inflammation; body weight status; cardiovascular disease; Canadians

1. Introduction

Serum ferritin (SF) is the storage form of iron in the body. Low serum concentrations of ferritin in the body is indicative of a negative iron balance and anemia, i.e., iron deficiency anemia [1–3]. SF is also an acute-phase reactant that elevates as part of a systemic response to inflammation [3–5] and is therefore recognized as a marker of inflammation [3,6]. Chronic inflammation can cause anemia, i.e., “anemia of inflammation” or “anemia of chronic disease”, and high SF concentrations induced by chronic inflammation may obscure iron deficiency anemia [2]. Given the key role of chronic inflammation in the causation of multiple chronic diseases [7–9], maintaining proper SF concentrations...
is a recognized strategy in their prevention [10–12]. The identification of novel ways to prevent and control inflammation are essential to this strategy.

The prohormone nutrient vitamin D has a key function in bone metabolism and is increasingly recognized for its anti-inflammatory effect [13–16]. However, the potential influence of vitamin D on SF concentrations, as an inflammation marker, has received relatively little attention. Conclusions from existing and mostly cross-sectional studies are inconsistent [2,17–23]. Therefore, the objective of this study is to shed more light on the cross-sectional associations of serum 25-hydroxyvitamin D (25(OH)D) with SF concentrations, and, importantly, to examine whether temporal increases in serum 25(OH)D concentrations are paralleled by the reduction in the SF concentrations. The latter would suggest a potential to influence SF concentrations by increasing 25(OH)D concentrations.

2. Materials and Methods

2.1. Study Design and Participants

We analyzed data collected as part of a preventative and integrative health program offered to community volunteers by the Pure North S’Energy Foundation (PN), a not-for-profit charitable organization. The primary objective of the PN program is lifestyle counselling and disease prevention. At enrolment, participants complete a lifestyle questionnaire, give a medical history, and have biometric measurements taken (height, weight, waist circumference, blood pressure) and blood drawn for the assessment of several biomarkers including serum 25(OH)D and SF concentrations. The collected information is used by health professionals to provide informed lifestyle counselling that includes personalized recommendations on diet, physical activity, dietary and vitamin D supplements, sleep and stress management. Follow-up visits are scheduled annually for health assessments and lifestyle counseling. Further information about the program can be found on the PN website [24]. Data collected from October 2007 through to April 2014 with granted written informed consent for use of the information for research purposes were used for the current analyses. All data were anonymized by PN prior to it being transferred to the University of Alberta for data analyses. Ethical approval was obtained from the Human Research Ethics Board at the University of Alberta.

Participants aged ≥18 years at baseline and with complete information on serum 25(OH)D concentrations and SF concentrations, one at baseline and one at the first follow-up visit, were considered for the present study. Those known to have kidney failure, have been taking medication for kidney failure, with a glomerular filtration rate of less than 15 mL/min per 1.73 m² or known to have cancer were excluded as those conditions themselves could cause elevated SF [25,26]. Participants with SF >1000 µg/L or C-reactive protein (CRP) concentration >10 mg/L were also excluded due to the possibility that such high concentrations were caused by an infection, an acute inflammation or an unknown condition rather than chronic inflammation [27]. The data for the present study included observations of 6812 participants, each with a baseline and a follow-up observation. The median time from baseline to follow-up was 11.67 months.

2.2. Serum Ferritin Concentrations

Immunoturbidimetric assay using the Beckman Coulter AU680® chemistry analyzer (Mississauga, ON, Canada) measured SF concentrations. Immunoassay reagent, K-Assay® Ferritin test kit (Cat. No. KAI-095), for use on the chemistry analyzer was obtained from Kamiya Biomedical (Seattle, WA, USA). The analytical measurable range was 6–1000 ng/L with coefficient of variance <5%. Temporal changes in SF concentrations were calculated by subtracting baseline concentrations from follow-up concentrations.

2.3. Serum 25(OH)D Concentrations

DiaSorin® Liaison chemiluminescent immunoassay with an inter-assay coefficient of variation of 11% was used to measure serum 25(OH)D concentrations. Serum 25(OH)D concentrations at baseline
and follow-up were categorized as <50, 50 to <75, 75 to <100, 100 to <125 and ≥125 nmol/L. The change in 25(OH)D was calculated by subtracting the baseline concentration from the follow-up concentration. Changes were then categorized into “No Improvement”, “Increased by <25”, “Increased by 25 to <50”, and “Increased by ≥50 nmol/L”.

2.4. Potential Confounding Variables

Gender, age, body weight status, blood pressure, smoking, alcohol consumption, physical activity and ethnicity were considered as potential confounders. Body mass index (BMI) was calculated for each participant as weight in kg/height² (kg/m²) and categorized as “Underweight” (BMI < 18.5 kg/m²), “Normal weight” (BMI = 18.5 to < 25 kg/m²), “Overweight” (BMI = 25 to < 30 kg/m²), and “Obesity” (BMI ≥ 30 kg/m²) [28]. Due to the small number of underweight participants, underweight and normal weight individuals were combined into a single group to achieve meaningful group sizes in the regression analysis. Blood pressure status was defined as “Normal” if systolic and diastolic pressures were <120/80 mmHg, and as “Elevated” if they were ≥120/80 mmHg or if the participant was using an anti-hypertensive medication [29]. Smoking status was defined as “Never smoker”, “Past smoker”, and “Current smoker”. Alcohol consumption status was categorized as “Non-drinker” for those who reported drinking <2 glasses per week and “Drinker” for those who drank ≥2 glasses per week, and ethnicity as “White” and “Non-white”. Physical activity levels were determined by estimating the metabolic equivalent of task (MET) per week for each physical activity reported. MET values were then multiplied by the time participants reportedly spent performing those activities per week (MET × hours per week). The total for each week was categorized as “low (<10 MET hours/week)”, “moderate (10 to <20 MET hours/week)” and “high (≥20 MET hours/week)”. MET hours per week at baseline were subtracted from the MET hours per week at the follow-up visit to determine change in physical activity. Change in physical activity was categorized as “Negative change” if MET hours per week were greater at baseline than at the follow-up, “No change” if MET hours per week remained unchanged and “Positive change” if MET hours per week were greater at the follow-up than baseline. Participants were asked the type and amount of supplementation they were using. Based on their responses related to vitamin D and multivitamin supplementation, the amount of vitamin D was calculated. Missing observations for confounding variables were treated as separate covariate categories and grouped as “Missing”.

2.5. Statistical Analyses

Percentages, medians with interquartile range, and means with standard deviation at both baseline and the follow-up are presented as descriptive statistics. Multiple linear regression analyses with repeated measures were used to identify the cross-sectional association of serum 25(OH)D and SF concentrations at baseline and the follow-up. These associations were adjusted for the confounding potential of age, gender, body weight status, blood pressure status, smoking status, alcohol consumption, physical activity level, and ethnicity. Although the distribution of SF concentrations is skewed, the residuals of the regression model were not skewed: A log transformation of SF concentrations is therefore not needed. Multiple linear regression models without repeated measures were used to identify the relationship of temporal changes in 25(OH)D with temporal changes in SF concentrations. These analyses were adjusted for baseline SF concentration, baseline serum 25(OH)D concentration, baseline age, gender, baseline body weight status, baseline values for blood pressure status, smoking status, alcohol consumption, and physical activity, and ethnicity. Analyses were stratified by gender and body weight status because SF concentrations vary considerably across their subgroupings. The above-mentioned regression analyses were further adjusted for CRP concentrations to quantify the associations of 25(OH)D with SF independent of the effect of CRP. All statistical analyses were performed using Stata, version 15.0 (Stata Corp, College Station, TX, USA) with statistical significance at 0.05.
3. Results

Participant characteristics are shown in Tables 1 and 2. Mean and median 25(OH)D concentrations at baseline, 87.2 and 80.7 nmol/L respectively, increased to 121.4 and 115.0 nmol/L respectively, at the follow-up. Mean and median SF concentrations at baseline, 160.6 µg/L and 122.0 µg/L respectively, decreased to 132.3 and 92.0 µg/L respectively, at the follow-up. The prevalence of elevated SF, 16.3% at baseline, also decreased to 11.5% at the follow-up (Table 1). Participants were 50.6 years of age, 30.0% was overweight and 26.4% obese (Table 2). At baseline, 46.9% of participants reported taking vitamin D-containing supplements with a median dose 3000 IU per day (Table 2), which increased to 75.8% with a median dose 7000 IU per day at the follow-up.

Table 3 depicts the cross-sectional associations of serum 25(OH)D and SF concentrations for the baseline and follow-up observations. Compared to participants with 25(OH)D concentrations of <50 nmol/L, those with 25(OH)D concentrations of ≥125 nmol/L had, on average, SF concentrations that were 27.59 µg/L lower. Participants with 25(OH)D concentrations of 75 to <100 nmol/L and of 100 to <125 nmol/L had statistically significant lower SF concentrations compared to those with 25(OH)D concentrations of <50 nmol/L. These differences appeared to be generally more pronounced among men and among those with excess body weight (Table 3). When further adjusted for the potential influence of CRP, the associations of serum 25(OH)D with SF concentrations appeared very similar in magnitude and statistical significance as those presented in Table 3.

Table 4 depicts the associations of temporal changes in 25(OH)D concentrations with temporal changes in SF concentrations. Compared to participants without temporal improvements in 25(OH)D concentrations between baseline and the follow-up, those who improved their 25(OH)D concentrations with ≥50 nmol/L had on average a decrease in their SF concentrations of 5.71 µg/L. For participants for whom their 25(OH)D concentrations increased with less than 50 nmol/L, the decrease in SF concentrations was less and not statistically significant. The only gender and weight status subgroups that depicted a statistically significant decrease in SF concentrations were obese participants, female and male participants combined; male participants; and obese male participants (Table 4). When further adjusted for the potential influence of CRP, the associations of temporal changes in 25(OH)D concentrations with temporal changes in SF concentrations appeared very similar in magnitude and statistical significance as those presented in Table 4. Statistically significant associations were observed only in those same subgroups where statistically significant associations were observed without the CRP adjustment (obese participants, female and male participants combined; male participants; and obese male participants).

Table 1. Serum 25(OH)D and serum ferritin levels at baseline and at the follow-up of 6812 study participants.

| Characteristic                        | At Baseline | At Follow-Up |
|--------------------------------------|-------------|--------------|
| **Serum 25(OH)D, nmol/L**           |             |              |
| Mean (SD)                            | 87.2 (41.6) | 121.4 (48.9) |
| Median (IQR)                         | 80.7 (59.5–106.0) | 115.0 (88.0–148.0) |
| **Serum ferritin, µg/L**             |             |              |
| Mean (SD)                            | 160.6 (139.5) | 132.3 (126.0) |
| Median (IQR)                         | 122.0 (64.0–212.0) | 92.0 (47.0–174.0) |
| **Elevated serum ferritin, %**       |             |              |
| No                                   | 83.7        | 88.5         |
| Yes (≥300 ng/mL for males and ≥200 ng/mL for females) | 16.3 | 11.5 |

Abbreviations: 25(OH)D—25 hydroxy vitamin D; SD—Standard Deviation; IQR—Inter Quartile Range.
Table 2. Baseline characteristics of 6812 study participants.

| Characteristics                      |       |
|--------------------------------------|-------|
| **Age, years**                       | Mean (SD) 50.6 (15.2) |
| **Gender (%)**                       |       |
| Female                               | 51.8  |
| Male                                 | 48.2  |
| **Body weight status, %**            |       |
| Under weight                         | 1.2   |
| Normal weight                        | 34.4  |
| Overweight                           | 38.0  |
| Obesity                              | 26.4  |
| **Blood pressure, %**                |       |
| Normal (<120/80 mmHg)                | 31.1  |
| Elevated (≥120/80 mmHg or anti-hypertensive medication use) | 65.4  |
| Missing                              | 3.4   |
| **Smoking status, %**                |       |
| Never smoker                         | 39.7  |
| Ex-smoker                            | 21.8  |
| Current smoker                       | 9.3   |
| Missing                              | 29.2  |
| **Alcohol consumption status, %**    |       |
| Non-drinker                          | 31.1  |
| Drinker                              | 36.4  |
| Missing                              | 32.4  |
| **Physical activity level, %**       |       |
| Low                                  | 28.6  |
| Moderate                             | 21.5  |
| High                                 | 20.9  |
| Missing                              | 28.9  |
| **Ethnicity**                        |       |
| White                                | 63.4  |
| Non-white                            | 36.6  |
| **Use of vitamin D-containing supplements, %** |       |
| No                                   | 35.3  |
| Yes                                  | 46.9  |
| Missing                              | 17.8  |
| **Vitamin D dose of the supplements, Median (IQR) IU/day** | 3000 (2000–5000) |

Abbreviations: SD—Standard Deviation; IQR—Inter Quartile Range.
Table 3. Cross-sectional associations of serum 25(OH)D and serum ferritin concentrations at baseline and follow-up.

| 25(OH)D, nmol/L | Number of Observations | All Participants | Under/Normal Body Weight | Overweight and Not Obese | Obesity |
|-----------------|------------------------|------------------|--------------------------|--------------------------|---------|
|                 | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       |
|                 | All observations (n = 13624) |                 |                           |                           |         |         |         |         |
| <50             | 1289       | ref     | ref      | ref      | ref      | ref      | ref      | ref      |
| 50 to <75       | 2729       | -3.36 (-9.60, 2.88) | 0.291 | 1.75 (-8.76, 12.26) | 0.744 | 0.97 (-10.53, 12.47) | 0.869 | -6.77 (-18.00, 4.45) | 0.237 |
| 75 to <100      | 3193       | -13.00 (-19.34, -6.65) | <0.001 | -1.56 (-11.82, 8.70) | 0.765 | -11.90 (-23.47, -0.33) | 0.044 | -15.27 (-27.43, -3.10) | 0.014 |
| 100 to <125     | 2574       | -23.15 (-29.91, -16.39) | <0.001 | -8.46 (-19.05, 2.14) | 0.118 | -17.68 (-29.95, -5.40) | 0.005 | -40.19 (-53.67, -26.70) | <0.001 |
| ≥125            | 3839       | -27.59 (-34.68, -20.51) | <0.001 | -12.39 (-23.25, -1.53) | 0.025 | -27.60 (-40.51, -14.68) | <0.001 | -33.02 (-47.51, -18.53) | <0.001 |

Among females (n = 7062)

| 25(OH)D, nmol/L | Number of Observations | All Participants | Under/Normal Body Weight | Overweight and Not Obese | Obesity |
|-----------------|------------------------|------------------|--------------------------|--------------------------|---------|
|                 | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       |
|                 | Among females (n = 7062) |                 |                           |                           |         |         |         |         |
| <50             | 412        | ref     | ref      | ref      | ref      | ref      | ref      | ref      |
| 50 to <75       | 1207       | -6.51 (-12.85, -0.17) | 0.044 | 2.43 (-8.21, 13.07) | 0.654 | -6.54 (-19.26, 6.17) | 0.313 | -11.63 (-23.00, -0.26) | 0.045 |
| 75 to <100      | 1722       | -13.67 (-20.02, -7.32) | <0.001 | 1.37 (-8.95, 11.69) | 0.795 | -14.98 (-27.55, -2.42) | 0.019 | -23.35 (-35.66, -11.05) | <0.001 |
| 100 to <125     | 1484       | -14.38 (-21.03, -7.73) | <0.001 | -0.57 (-11.11, 9.98) | 0.916 | -13.94 (-26.98, -0.90) | 0.036 | -26.85 (-40.34, -13.36) | <0.001 |
| ≥125            | 2237       | -20.65 (-27.56, -13.75) | <0.001 | -4.75 (-15.35, 5.85) | 0.38  | -22.71 (-36.52, -8.90) | 0.001 | -31.26 (-45.87, -16.65) | <0.011 |

Among males (n = 6562)

| 25(OH)D, nmol/L | Number of Observations | All Participants | Under/Normal Body Weight | Overweight and Not Obese | Obesity |
|-----------------|------------------------|------------------|--------------------------|--------------------------|---------|
|                 | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       | β (95% CI) | p       |
|                 | Among males (n = 6562) |                 |                           |                           |         |         |         |         |
| <50             | 877        | ref     | ref      | ref      | ref      | ref      | ref      | ref      |
| 50 to <75       | 1522       | 1.71 (-8.92, 12.34) | 0.753 | 7.46 (-14.67, 29.59) | 0.509 | 5.81 (-11.11, 22.74) | 0.501 | -2.32 (-20.89, 16.25) | 0.807 |
| 75 to <100      | 1471       | -8.97 (-19.98, 2.05) | 0.111 | 2.13 (-19.82, 24.09) | 0.849 | -8.96 (-26.24, 8.32) | 0.31  | -11.64 (-31.86, 8.58) | 0.259 |
| 100 to <125     | 1090       | -32.22 (-44.20, -20.25) | <0.001 | -16.49 (-39.88, 6.89) | 0.167 | -21.35 (-40.06, -2.64) | 0.025 | -52.99 (-75.41, -30.58) | <0.001 |
| ≥125            | 1602       | -34.75 (-47.45, -22.04) | <0.001 | -22.91 (-48.07, 2.24) | 0.074  | -31.27 (-50.82, -11.73) | 0.002 | -32.94 (-56.78, -9.11) | 0.007 |

p-values from multiple linear regression model were adjusted for gender (except the gender stratified analyses), age, body weight status (except the analyses stratified by body weight status), blood pressure status, smoking status, alcohol status, physical activity level and ethnicity.
Table 4. Associations of temporal changes in serum 25(OH)D concentrations with coinciding changes in serum ferritin concentrations by gender and body weight status.

| Number of Participants | All Participants | Under/Normal Body Weight | Overweight and Not Obese | Obesity |
|------------------------|------------------|--------------------------|--------------------------|---------|
|                        | β (95% CI)       | β (95% CI)               | β (95% CI)               | β (95% CI) |
|                        | p                | p                        | p                        | p        |
| All observations (n = 6812) |                  |                          |                          |          |
| Change in 25(OH)D, nmol/L |                  |                          |                          |          |
| No improvement         | 1390             | ref                      | ref                      | ref      |
| Increase by <25        | 1667             | 1.85 (−3.04, 6.74)       | 0.458 (0.43 (−5.71, 6.58) | 0.889 (3.62 (−4.58, 11.82) | 0.386 (−1.90 (−13.30, 9.49) |
| Increase by 25 to <50   | 1562             | −2.23 (−7.35, 2.89)      | 0.394 (−1.96 (−8.41, 4.49) | 0.551 (−0.88 (−9.35, 7.60) | 0.839 (−5.60 (−17.62, 6.41) | 0.360 |
| Increase by ≥50        | 2193             | −5.71 (−10.61, −0.82)    | 0.022 (−3.16 (−9.22, 2.90) | 0.307 (−5.84 (−14.01, 2.33) | 0.161 (−12.62 (−24.16, −1.08) | 0.032 |

Among females (n = 3531)

| Change in 25(OH)D, nmol/L |                  |                          |                          |          |
| No improvement            | 745              | ref                      | ref                      | ref      |
| Increase by <25           | 864              | 0.003 (−3.70, 3.70)      | 0.999 (−0.59 (−5.26, 4.08) | 0.804 (−3.47 (−10.90, 3.94) | 0.358 (4.24 (−4.60, 13.09) |
| Increase by 25 to <50     | 824              | −1.84 (−5.73, 2.03)      | 0.351 (0.78 (−4.16, 5.73) | 0.756 (−6.56 (−14.24, 1.13) | 0.095 (0.67 (−8.48, 9.82) | 0.886 |
| Increase by ≥50           | 1098             | −0.94 (−4.69, 2.80)      | 0.622 (−0.17 (−4.75, 4.41) | 0.941 (−5.62 (−13.17, 1.93) | 0.144 (4.20 (−5.06, 13.46) | 0.373 |

Among males (n = 3281)

| Change in 25(OH)D, nmol/L |                  |                          |                          |          |
| No improvement            | 645              | ref                      | ref                      | ref      |
| Increase by <25           | 803              | 2.96 (−6.05, 11.96)      | 0.520 (3.68 (−12.52, 19.88) | 0.656 (7.89 (−4.77, 20.56) | 0.222 (−4.60 (−23.30, 14.10) |
| Increase by 25 to <50     | 738              | −3.19 (−12.62, 6.25)     | 0.508 (−3.59 (−20.34, 13.16) | 0.674 (0.40 (−12.67, 13.47) | 0.952 (−9.06 (−29.12, 10.99) | 0.375 |
| Increase by ≥50           | 1095             | −9.75 (−18.69, −0.82)    | 0.032 (−7.87 (−24.17, 8.42) | 0.343 (−5.35 (−17.75, 7.04) | 0.397 (19.77 (−38.22, −1.31) | 0.036 |

p-values from multiple linear regression model were adjusted for baseline serum ferritin, baseline serum 25(OH)D concentration, baseline age, baseline body weight status (except the analyses stratified by body weight status), baseline blood pressure status, baseline smoking status, baseline alcohol status, baseline physical activity level, ethnicity and gender (except the gender stratified analyses).
4. Discussion

We compared serum 25(OH)D and SF concentrations both cross-sectionally and longitudinally. The cross-sectional comparisons revealed strong and mostly statistically significant inverse associations. In contrast, the longitudinal comparisons revealed modest associations for those participants who improved their 25(OH)D concentrations with ≥50 nmol/L compared to those who did not improve their 25(OH)D concentrations. These longitudinal comparisons showed the absence of statistically significant associations between 25(OH)D and SF concentrations for those participants who improved their 25(OH)D concentrations with <50 nmol/L, for participants with normal weight and participants who were overweight, and for participating women.

Cross-sectional studies reported high SF concentrations and a high prevalence of anemia based on low mean hemoglobin concentration among adults [23] and elderly [30] with vitamin D deficiency in the United States. Coutard et al. [31] in contrast, did not find this for hospitalized geriatric patients in France. Castro et al. [32] did not observe an association of vitamin D with SF concentrations among ambulatory patients with inflammatory bowel disease in Portugal, whereas Andiran et al. [33] did demonstrate such an association among children and adolescents who attended an outpatient clinic in Turkey. None of the above studies had considered potential confounders when examining the associations between vitamin D and SF, which complicates cross-study comparisons. A recent population-based cross-sectional study that considered important confounders reported inverse associations between serum 25(OH)D and SF among Korean men [18]. With respect to Korean women, they reported a positive association for pre-menopausal women and an absence of an association for post-menopausal women [18], following an earlier report of iron deficiency anemia and anemia of inflammation for both pre- and post-menopausal women of low vitamin D status [34]. In the present study, the cross-sectional comparisons had revealed an inverse association for both women and men, although the magnitude of the associations was somewhat more pronounced for men compared to women. Another recent population-based cross-sectional study that considered various confounders reported inverse associations for normal weight Canadians but not for overweight and obese Canadians [35]. This seems to contrast the cross-sectional observations of the present study where the associations among obese participants were more pronounced. We note important differences across the studies: The Korean study [34] and the Canadian study [35] were population-based whereas the present study included volunteer participants of a preventive health program with the majority of participants reportedly using vitamin D supplements in a country where the prevalence of iron deficiency anemia is low because of mandatory fortification of wheat flour [36].

The potential of vitamin D to lower SF concentrations has received little attention in intervention studies. The single randomized controlled trial in this area demonstrated that supplementation with 400 to 1000 IU of vitamin D per day for a period of 16 weeks increased serum 25(OH)D concentration from 28.7 nmol/L to 48.8 nmol/L while SF concentrations remained unchanged [20]. The present study evaluated a preventive health program where participants used higher doses (at the follow-up, median doses were 7000 IU per day) which achieved serum 25(OH)D concentrations to increase, on average, from 87.2 nmol/L to 121.4 nmol/L. Only in the subgroup with increases in excess of 50 nmol/L, did we observe a statistically significant reduction in SF concentrations. Subgroups with smaller increases did not show a decrease in SF concentrations. Because in the above mentioned randomized controlled trial the increase in 25(OH)D concentrations was on average 20.1 nmol/L (48.8–28.7) [20], both studies seem consistent in their findings that increases in 25(OH)D concentrations of less than 50 nmol/L do not affect SF concentrations.

Current vitamin D recommendations by the Institute of Medicine are to achieve 25(OH)D concentrations of 50 nmol/L as this level ensures good bone health [37]. Other institutions, include the Endocrine Society [38], the National Osteoporosis Society [39] Osteoporosis Canada [40], the Multiple Sclerosis Society of Canada [41], and the American Geriatrics Society [42], recommend higher serum 25(OH)D concentrations (≥75 nmol/L) with the aim to achieve various other health benefits. An increase of 25 nmol/L (i.e., from the recommendation of 50 nmol/L to the recommendation of
75 nmol/L) does not seem enough to affect SF concentrations as the present study revealed that only participants who improved their 25(OH)D concentrations with ≥ 50 nmol/L showed reductions in SF concentrations. These associations appeared largely independent of the influence of CRP. Another investigation of the potential anti-inflammatory role of vitamin D had suggested that obese subjects reduced the risk of having elevated CRP serum concentrations by increasing their serum 25(OH)D concentrations [15]. This reduction in the risk of elevated CRP concentrations among obese subjects occurred in response to not only increases in 25(OH)D concentrations of ≥ 50 nmol/L, but also for smaller changes [15]. As both inflammation markers, SF and CRP, also predict adverse cardiovascular events, we recommend intervention studies that achieve high 25(OH)D concentrations to establish their combined benefits in terms of preventing cardiovascular disease among obese subjects.

Strengths of the present study include its longitudinal design, large sample size, the availability of information on various confounders and the wide range of serum 25(OH)D concentrations. We acknowledge that this study was conducted among volunteer participants of a preventive health program who are not representatives of the general population. The preventive health program not only encourages supplementation with vitamin D, but rather healthy lifestyles in general. The latter may have affected the findings of the present study. Caution is therefore warranted in the interpretation and generalization of the present findings.

5. Conclusions

The present study suggests that despite strong cross-sectional associations between 25(OH)D and SF concentrations, interventions that aim to lower SF concentrations through sun-exposure and vitamin D supplementation should target substantial increases in 25(OH)D concentrations. We recommend such intervention studies to establish the combined anti-inflammatory and cardiovascular benefits.

Author Contributions: L.L.M. and P.J.V. devised the study and drafted the manuscript. L.L.M. conducted the statistical analysis whereby J.P.E. and P.J.V. advised. L.L.M. conducted the literature review. All authors advised on the interpretation of the findings, and all authors reviewed, edited and approved the final version of the manuscript.

Funding: This research was funded through a Canada Research Chair in Population Health and an Alberta Research Chair in Nutrition and Disease Prevention to P.J.V.

Acknowledgments: The authors wish to thank the Pure North S’Energy Foundation for allowing their data to be analyzed for the purpose of this article, and specifically Peter Tran and Ken Fyle for the management and validation of the data. P.J.V. holds an Alberta Research Chair in Nutrition and Disease Prevention and it is awarded by the School of Public Health at the University of Alberta through a thematic research contract with the Pure North S’Energy Foundation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Nairz, M.; Theurl, I.; Wolf, D.; Weiss, G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wien. Med. Wochenschr. 2016, 166, 411–423. [CrossRef]
2. Smith, E.M.; Tangpricha, V. Vitamin D and anemia: Insights into an emerging association. Curr. Opin. Endocrinol. Diabetes Obes. 2015, 22, 432–438. [CrossRef]
3. Kell, D.B.; Pretorius, E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics 2014, 6, 748–773. [CrossRef]
4. Langer, A.L.; Ginzburg, Y.Z. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodial. Int. 2017, 21, S37–S46. [CrossRef]
5. Pan, Y.; Jackson, R.T. Ethnic difference in the relationship between acute inflammation and serum ferritin in US adult males. Epidemiol. Infect. 2008, 136, 421–431. [CrossRef] [PubMed]
6. Alkhateeb, A.A.; Leitzel, K.; Ali, S.M.; Campbell-Baird, C.; Evans, M.; Fuchs, E.M.; Kostler, W.J.; Lipton, A.; Connor, J. Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy. PLoS ONE 2012, 7, e51379–e51384. [CrossRef]
7. Franceschi, C.; Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J. Gerontol. Ser. A Biomed. Sci. Med Sci*. 2014, 69, S4–S9. [CrossRef]

8. Khansari, N.; Shakiba, Y.; Mahmoudi, M. Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. *Recent Pat. Inflamm. Allergy Drug Discov*. 2009, 3, 73–80. [CrossRef] [PubMed]

9. Shacter, E.; Weitzman, S.A. Chronic inflammation and cancer. *Oncology* 2002, 16, 217–229.

10. Gonzalez, A.S.; Guerrero, D.B.; Soto, M.B.; Diaz, S.P.; Martinez-Olmos, M.; Vidal, O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. *Eur. J. Clin. Nutr*. 2006, 60, 802–809. [CrossRef] [PubMed]

11. Kiechl, S.; Willeit, J.; Egger, G.; Poewe, W.; Oberhollenzer, F. Body Iron Stores and the Risk of Carotid Atherosclerosis: Prospective Results from the Bruneck Study. *Circulation* 1997, 96, 3300–3307. [CrossRef]

12. Cutler, P. Deferoxamine therapy in high-ferritin diabetes. *Diabetes* 1989, 38, 1207–1210. [CrossRef] [PubMed]

13. De Oliveira, C.; Biddulph, J.P.; Hirani, V.; Schneider, I.J.C. Vitamin D and inflammatory markers: Cross-sectional analyses using data from the English Longitudinal Study of Ageing (ELSA). *J. Nutr. Sci*. 2017, 6, e1–e6. [CrossRef]

14. Azizieh, F.; Alyahya, K.O.; Raghupathy, R. Association between levels of vitamin D and inflammatory markers in healthy women. *J. Inflamm. Res*. 2016, 9, 51–57. [CrossRef] [PubMed]

15. Mastroeni, S.S.; Munasinghe, L.L.; Pham, T.M.; Loehr, S.A.; Ekwaru, J.P.; Mastroeni, M.F.; Veugelers, P.J. The Effect of Serum 25-Hydroxyvitamin D Concentrations on Elevated Serum C-Reactive Protein Concentrations in Normal Weight, Overweight and Obese Participants of a Preventive Health Program. *Nutrients* 2016, 8, 696. [CrossRef]

16. Yin, K.; Agrawal, D.K. Vitamin D and inflammatory diseases. *J. Inflamm. Res*. 2014, 7, 69–87. [PubMed]

17. Malczewska-Lenczowska, J.; Sitkowski, D.; Surala, O.; Orysiak, J.; Szczepanska, B.; Witek, K. The Association between Iron and Vitamin D Status in Female Elite Athletes. *Nutrients* 2018, 10, 167. [CrossRef]

18. Seong, J.M.; Yoon, Y.S.; Lee, K.S.; Bae, N.Y.; Gi, M.Y.; Yoon, H. Gender difference in relationship between serum ferritin and 25-hydroxyvitamin D in Korean adults. *PLoS ONE* 2017, 12, e0177722–e30177735. [CrossRef]

19. Azizi-Soleiman, F.; Vafa, M.; Abiri, B.; Safavi, M. Effects of iron on Vitamin D metabolism: A systematic review. *Int. J. Prev. Med*. 2016, 7, 126–131. [CrossRef]

20. Madar, A.A.; Stene, L.C.; Meyer, H.E.; Brekke, M.; Lagerlov, P.; Knutsen, K.V. Effect of vitamin D3 supplementation on iron status: A randomized, double-blind, placebo-controlled trial among ethnic minorities living in Norway. *Nutr. J*. 2016, 15, 74–84. [CrossRef]

21. Monlezun, D.J.; Camargo, C.A., Jr.; Mullen, J.T.; Quraishi, S.A. Vitamin D Status and the Risk of Anemia in Community-Dwelling Adults: Results from the National Health and Nutrition Examination Survey 2001–2006. *Medicine* 2015, 94, e1799–e1805. [CrossRef] [PubMed]

22. Blanco-Rojo, R.; Perez-Granados, A.M.; Toxqui, L.; Zazo, P.; de la Piedra, C.; Vaquero, M.P. Relationship between vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food. *Eur. J. Nutr*. 2013, 52, 695–703. [CrossRef]

23. Sim, J.J.; Lac, P.T.; Liu, I.L.; Meguerditchian, S.O.; Kumar, V.A.; Kujubu, D.A.; Rasgon, S.A. Vitamin D deficiency and anemia: A cross-sectional study. *Ann. Hematol*. 2010, 89, 447–452. [CrossRef]

24. Pure North—2019 Program Options. Available online: http://purenorth.ca (accessed on 10 December 2017).

25. Koperdanova, M.; Cullis, J.O. Interpreting raised serum ferritin levels. *Br. Med J*. 2015, 351, h3692–h3695. [CrossRef] [PubMed]

26. Bacon, B.R.; Adams, P.C.; Kowdley, K.V.; Powell, L.W.; Tavill, A.S. American Association for the Study of Liver, D. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology* 2011, 54, 328–343.

27. Pearson, T.A. Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003, 107, 499–511. [CrossRef] [PubMed]

28. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (NIH Publication No. 98-4083). 1998. Available online: https://www.ncbi.nlm.nih.gov/books/NBK2003/pdf/Bookshelf_NBK2003.pdf (accessed on 10 January 2019).
29. Cifu, A.S.; Davis, A.M. Prevention, detection, evaluation, and management of high blood pressure in adults. *J. Am. Med Assoc.* 2017, 318, 2132–2134. [CrossRef] [PubMed]
30. Perlstein, T.S.; Pande, R.; Berliner, N.; Vanasse, G.J. Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: Association with anemia of inflammation. *Blood* 2011, 117, 2800–2806. [CrossRef]
31. Coutard, A.; Garlandt, R.; Estivin, S.; Andro, M.; Gentric, A. Association of vitamin D deficiency and anemia in a hospitalized geriatric population: Denutrition as a confounding factor. *Ann. Hematol.* 2013, 92, 615–619. [CrossRef] [PubMed]
32. Castro, F.D.; Magalhaes, J.; Carvalho, P.B.; Moreira, M.J.; Mota, P.; Cotter, J. Lower Levels of Vitamin D Correlate with Clinical Disease Activity and Quality of Life in Inflammatory Bowel Disease. *Arch. Gastroenterol.* 2015, 52, 260–265. [CrossRef] [PubMed]
33. Andiran, N.; Celik, N.; Akca, H.; Dogan, G. Vitamin D deficiency in children and adolescents. *J. Clin. Res. Pediatr. Endocrinol.* 2012, 4, 25–29. [CrossRef] [PubMed]
34. Shin, J.Y.; Shim, J.Y. Low vitamin D levels increase anemia risk in Korean women. *Int. J. Clin. Chem.* 2013, 421, 177–180. [CrossRef] [PubMed]
35. Munasinghe, L.L.; Ekwaru, J.P.; Mastroeni, M.F.; Mastroeni, S.S.; Veugelers, P.J. The association of serum 25-hydroxyvitamin D concentrations with elevated serum ferritin levels in normal weight, overweight and obese Canadians. *PLoS ONE* 2019, 14, e0213260–e0213274. [CrossRef] [PubMed]
36. Food and Drug Regulations. C.R.C., c.870 (B.13.001). 2018. Available online: https://laws-lois.justice.gc.ca/PDF/C.R.C.,_c._870.pdf (accessed on 5 January 2019).
37. Institute of Medicine. *Dietary Reference Intakes for Calcium and Vitamin D*; National Academies Press: Washington, DC, USA, 2011.
38. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M.; Endocrine, S. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *J. Clin. Endocrinol. Metab.* 2011, 96, 1911–1930. [CrossRef] [PubMed]
39. Aspray, T.J.; Bowring, C.; Fraser, W.; Gittoes, N.; Javaid, M.K.; Macdonald, H.; Patel, S.; Selby, P.; Tanna, N.; Francis, R.M.; National Osteoporosis Society. National Osteoporosis Society Vitamin D guideline summary. *Age Ageing* 2014, 43, 592–595. [CrossRef] [PubMed]
40. Hanley, D.A.; Cranney, A.; Jones, G.; Whiting, S.J.; Leslie, W.D.; Cole, D.E.; Atkinson, S.A.; Josse, R.G.; Feldman, S.; Kline, G.A.; et al. Vitamin D in adult health and disease: A review and guideline statement from Osteoporosis Canada. *Can. Med. Assoc. J.* 2010, 182, E610–E618. [CrossRef] [PubMed]
41. Multiple Sclerosis Society of Canada. Vitamin D and Multiple Sclerosis Recommendations. Available online: https://mssociety.ca/library/document/Vka6RXcnOizNm9slwuWvroejlhLqTJ8/original.pdf (accessed on 30 January 2019).
42. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for Prevention of Falls and Their Consequences. *J. Am. Geriatr. Soc.* 2014, 62, 147–152.